Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
← catalyst calendarNCT07226999 · readout in 1,395 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
550estimated
Sites
83
Countries
Australia, China, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-09 | actual | When the study began enrolling |
| Primary completion | 2030-06-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2034-03-11 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Small Cell Lung Cancer (SCLC)
Interventions
- Drug: PF-08634404
- Biological: Atezolizumab
- Drug: Chemotherapy
Primary outcomes
what the primary-completion date above is the date OFPhase 2: Confirmed Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] based on the investigator's assessment
measured Up to approximately 2 years after completion of study treatment of last study participant
Phase 2: Number of participants with treatment-emergent adverse events
measured Up to 90 days after the last dose of treatment
Phase 3: Overall Survival (OS)
measured Up to approximately 2 years after completion of study treatment of last study participant
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed